[Neuroleptic therapy of schizophrenia from pharmacological viewpoint].
D000818:Animals; D001058:Apomorphine / Q000037:antagonists & inhibitors; D001143:Arousal / Q000187:drug effects; D002421:Caudate Nucleus / Q000187:drug effects; D002746:Chlorpromazine / Q000494:pharmacology; D002749:Chlorprothixene / Q000494:pharmacology; D004569:Electroencephalography; D005476:Fluphenazine / Q000494:pharmacology; D006220:Haloperidol / Q000494:pharmacology; D006801:Humans; D008728:Methotrimeprazine / Q000494:pharmacology; D010546:Perphenazine / Q000494:pharmacology; D010640:Phenothiazines / Q000494:pharmacology; D011395:Promazine / Q000494:pharmacology; D051381:Rats; D012018:Reflex / Q000187:drug effects; D012559:Schizophrenia / Q000188:drug therapy*; D013881:Thioridazine / Q000494:pharmacology; D014149:Tranquilizing Agents / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use
D010640:Phenothiazines; D014149:Tranquilizing Agents; D008728:Methotrimeprazine; D002749:Chlorprothixene; D010546:Perphenazine; D006220:Haloperidol; D001058:Apomorphine; D013881:Thioridazine; D011395:Promazine; D005476:Fluphenazine; D002746:Chlorpromazine
Die Neuroleptikantherapie der Schizophrenie inpharmakologischer Sicht.